Drug Resistance‑related Gene Targets and Molecular Mechanisms in the A2780/Taxol‑resistant Epithelial Ovarian Cancer Cell Line

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Apr 8

PMID 38586210

Authors

Ruihui Yang

Huainian Zhang

Zexin Chen

Tao Zhang

Peng Wei

Huaguo Liang

Yaoyao He

Changtao Zheng

Xicheng Wang

Yongli Zhang

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer (EOC) is a fatal gynecological malignant tumor with a low 5-year survival rate. The use of the first-line chemotherapeutic drug, paclitaxel, for the treatment of EOC is associated with resistance, often leading to treatment failure. The present study investigated the gene targets in an A2780 paclitaxel-resistant EOC cell line (A2780/Taxol), and the potential underlying mechanisms using transcriptome sequencing technology and bioinformatics analysis. The transcriptome of the A2780/Taxol cell line was sequenced, and 498 differentially expressed genes were obtained contained in the Gene Expression Omnibus dataset. Further bioinformatics analysis revealed that matrix metalloproteinase 1 (MMP1), zyxin (ZYX) and Unc-5 netrin receptor C (UNC5C) may be gene targets related to paclitaxel resistance. Moreover, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis indicated that a potential mechanism associated with paclitaxel resistance was related to cell migration. Furthermore, the expression levels of MMP1, ZYX and UNC5C were verified using western blotting, immunofluorescence and immunohistochemistry . The results revealed that the expression levels of MMP1 and ZYX were significantly increased in A2780/Taxol cells, while UNC5C expression was significantly decreased, which was consistent with the results of the transcriptome sequencing. The present study demonstrated that MMP1, ZYX and UNC5C may be the gene targets associated with paclitaxel resistance in EOC. These genes have potential to be used as molecular markers for EOC drug therapy, targeted elimination of drug resistance, and evaluation of treatment efficacy and patient prognosis.

References

Wang J, Rojas P, Mao J, Sadurni M, Garnier O, Xiao S . Persistence of RNA transcription during DNA replication delays duplication of transcription start sites until G2/M. Cell Rep. 2021; 34(7):108759. PMC: 7900609. DOI: 10.1016/j.celrep.2021.108759. View

Liao Y, Chiang K, Shieh J, Huang C, Shen C, Huang W . Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma. Oncogene. 2016; 36(16):2228-2242. PMC: 5415642. DOI: 10.1038/onc.2016.371. View

Sansing H, Sarkeshik A, Yates J, Patel V, Gutkind J, Yamada K . Integrin αβ1, αvβ, α6β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. Biochem Biophys Res Commun. 2011; 406(2):171-6. PMC: 3102534. DOI: 10.1016/j.bbrc.2011.01.109. View

Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T . Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int J Mol Sci. 2020; 21(11). PMC: 7312011. DOI: 10.3390/ijms21114002. View

Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H . New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother. 2021; 141:111824. DOI: 10.1016/j.biopha.2021.111824. View

Zhu Y, Tao Z, Chen Y, Lin S, Zhu M, Ji W . Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT. Breast Cancer Res Treat. 2022; 193(1):65-81. DOI: 10.1007/s10549-022-06514-6. View

Legerstee K, Geverts B, Slotman J, Houtsmuller A . Dynamics and distribution of paxillin, vinculin, zyxin and VASP depend on focal adhesion location and orientation. Sci Rep. 2019; 9(1):10460. PMC: 6639384. DOI: 10.1038/s41598-019-46905-2. View

Partynska A, Gomulkiewicz A, Dziegiel P, Podhorska-Okolow M . The Role of Zyxin in Carcinogenesis. Anticancer Res. 2020; 40(11):5981-5988. DOI: 10.21873/anticanres.14618. View

Feng Q, Li X, Sun W, Sun M, Li Z, Sheng H . Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1. Biochem Pharmacol. 2020; 178:114092. DOI: 10.1016/j.bcp.2020.114092. View

10.

Haunschild C, Tewari K . The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2020; 160(1):333-345. DOI: 10.1016/j.ygyno.2020.09.043. View

11.

Yuan M, Xie F, Xia X, Zhong K, Lian L, Zhang S . UNC5C‑knockdown enhances the growth and metastasis of breast cancer cells by potentiating the integrin α6/β4 signaling pathway. Int J Oncol. 2019; 56(1):139-150. PMC: 6910211. DOI: 10.3892/ijo.2019.4931. View

12.

Liu J, Zheng M, Qi Y, Wang H, Liu M, Liu Q . Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer. Int J Oncol. 2018; 53(4):1774-1786. DOI: 10.3892/ijo.2018.4496. View

13.

Xu Q, Du X, Huang T, Zheng Y, Li Y, Huang D . Role of Cell-Cell Junctions in Oesophageal Squamous Cell Carcinoma. Biomolecules. 2022; 12(10). PMC: 9599896. DOI: 10.3390/biom12101378. View

14.

Tulchinsky E, Demidov O, Kriajevska M, Barlev N, Imyanitov E . EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2018; 1871(1):29-39. DOI: 10.1016/j.bbcan.2018.10.003. View

15.

Shen Q, Hill T, Cai X, Bui L, Barakat R, Hills E . Physical confinement during cancer cell migration triggers therapeutic resistance and cancer stem cell-like behavior. Cancer Lett. 2021; 506:142-151. PMC: 8112468. DOI: 10.1016/j.canlet.2021.01.020. View

16.

Zhu S, Yang N, Niu C, Wang W, Wang X, Bai J . The miR-145-MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance. Pharmacol Res. 2022; 179:106196. DOI: 10.1016/j.phrs.2022.106196. View

17.

Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

18.

Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P . Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020; 5(1):193. PMC: 7479143. DOI: 10.1038/s41392-020-00300-w. View

19.

Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y, Yamamoto T . Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2021; 22(1). PMC: 7795499. DOI: 10.3390/ijms22010240. View

20.

Yang Y, Mao J, Tan X . Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med. 2020; 18(12):890-897. DOI: 10.1016/S1875-5364(20)60032-2. View